Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Market Size (2024 - 2029)

The Nucleic Acid Therapeutics Contract Development and Manufacturing Organization Market is projected to experience significant growth due to increasing investments in the development of nucleic acid therapeutics and the complexities associated with their manufacturing. The need for specialized expertise and equipment to address these complexities is driving the demand for CDMO services, which are crucial for the precise synthesis and effective delivery of therapeutics like mRNA and antisense oligonucleotides. Additionally, the expansion of CDMO facilities and strategic partnerships among market players are expected to further enhance the market's growth prospects. However, challenges such as strict regulatory guidelines and a lack of sufficient expertise in nucleic acid therapeutics may pose constraints on the market's expansion.

Market Size of Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Industry

Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 4.37 Billion
Market Size (2029) USD 8.88 Billion
CAGR (2024 - 2029) 12.60 %
Fastest Growing Market North America
Largest Market Asia Pacific
Market Concentration Medium

Major Players

Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Market Major Players

*Disclaimer: Major Players sorted in no particular order

Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Market Analysis

The Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Market size is estimated at USD 4.37 billion in 2024, and is expected to reach USD 8.88 billion by 2029, growing at a CAGR of 12.60% during the forecast period (2024-2029).

The market is growing, propelled by the increasing investment in developing nucleic acid therapeutics, complexities in manufacturing nucleic acid therapeutics, and the growing number of collaborations and partnerships with the market players. Complexities in manufacturing nucleic acid therapeutics, which require expertise in manufacturing like CDMO, are expected to drive market growth during the projected period. Manufacturing nucleic acid therapeutics presents unique challenges due to the intricate nature of these molecules and the need for precise, high-quality production. There are some complexities in nucleic acid therapeutic manufacturing, and CDMOs play a crucial role. Nucleic acid therapeutics, such as mRNA and antisense oligonucleotides, require precise synthesis of specific sequences.

CDMOs have specialized expertise and equipment for accurate and efficient synthesis. In addition, developing effective delivery systems, including lipid nanoparticles and viral vectors, is essential for ensuring the therapeutic reaches target cells. CDMOs have expertise in formulating and producing these carriers. Due to such complexities associated with the manufacturing of nucleic acid therapeutics, there is a need for CDMO expertise, thereby boosting the market growth between 2024 and 2029.

The increasing investment by the CDMO for expanding the CDMO facilities and services for nucleic acid therapeutics will likely boost the market from 2024 to 2029. For instance, Agilent Technologies Inc. announced that it will invest around USD 725 million to expand its manufacturing capacity for therapeutic nucleic acid. This investment is a testament to the high demand for therapeutic oligos and the exceptional quality and service of therapeutic oligo contract development and manufacturing organizations (CDMO). Additionally, in July 2023, Biovian announced a significant investment of over EUR 50 million (USD 52.7 million) to expand its manufacturing facility for viral vectors in Turku, Finland. Such high investment by the CDMO companies to develop the manufacturing facilities and services offering robust growth prospects are expected to propel the market during the projected period.

Additionally, rising partnerships and collaboration by the market players are expected to contribute to the market growth between 2024 and 2030. For instance, in January 2023, Charles River Laboratories International Inc. and Rznomics Inc. announced a viral vector contract development and manufacturing organization (CDMO) partnership. Rznomics will leverage Charles River’s viral vector CDMO experience to initiate clinical development of its RNA-based anticancer gene therapy in liver cancer patients. Similarly, in October 2022 and April 2022, BACHEM collaborated with Eli Lilly and Company to innovate and produce active pharmaceutical components derived from oligonucleotides, an emerging class of intricate nucleic acid treatments.

Hence, several complexities in manufacturing nucleic acid therapeutics, high investment costs, and market players' strategic collaboration are expected to boost the market between 2024 and 2029. Nevertheless, strict regulatory guidelines and insufficient expertise in nucleic acid therapeutics are expected to restrain the market.

Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Industry Segmentation

The nucleic acid therapeutics CDMO market refers to the products and services provided by CDMO companies for manufacturing nucleic acid therapeutics. These therapeutics can be produced by either CDMO companies or pharmaceutical companies.

The nucleic acid therapeutics CDMO market is segmented by product type, application, end user, and geography. By product type, the market is segmented into cell and gene therapy, mRNA therapy, viral vector vaccines, plasmid DNA, antisense oligonucleotides, and siRNA therapy. By application, the market is segmented by oncology, genetic disorders, infectious diseases, and others. By end user, the market is segmented by pharmaceutical and biotechnology and government and academic research institutes. By geography, the market is segmented by North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.

By Product Type
Cell and Gene Therapy
mRNA Therapy
Viral Vector Vaccines
Plasmid DNA
Antisense Oligonucleotides
siRNA Therapy
By Application
Oncology
Genetic Disorder
Infectious Diseases
Others
By End User
Pharmaceutical and Biotechnology
Government and Academic Research Institutes
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Spain
Italy
Rest of Europe
Asia-Pacific
India
Japan
China
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of the Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Market Size Summary

The nucleic acid therapeutics contract development and manufacturing organization market is poised for significant growth, driven by increasing investments and the complexities involved in manufacturing nucleic acid-based therapies. The demand for specialized expertise in the production of mRNA and antisense oligonucleotides, along with the need for precise synthesis and effective delivery systems, underscores the crucial role of CDMOs in this sector. The market is further bolstered by strategic collaborations and partnerships among key players, which enhance the development and production capabilities of these advanced therapeutics. The expansion of CDMO facilities and services, supported by substantial investments from both public and private sectors, is expected to propel the market forward, addressing the rising demand for therapeutic oligos and other nucleic acid-based treatments.

North America is a leading region in the nucleic acid therapeutics CDMO market, benefiting from a robust presence of established companies, startups, and favorable regulatory approvals. The region's market growth is supported by significant investments in CDMO services and strategic expansions by key players. The market's competitive landscape is characterized by strategic activities such as collaborations, partnerships, and facility expansions, which are essential for meeting the growing demand for nucleic acid therapeutics. Despite challenges like strict regulatory guidelines and the need for specialized expertise, the market is expected to experience robust growth, driven by the increasing complexity of therapeutic development and the strategic initiatives undertaken by market participants.

Explore More

Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Demand for Nucleic Acid Therapeutics Applications to Treat Chronic and Genetic Diseases

      2. 1.2.2 Complexities in Manufacturing Nucleic Acid Therapeutics and Increasing Partnerships and Collaborations

      3. 1.2.3 Increasing Pharmaceutical R&D Investments and Fundings

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Government Regulations

      2. 1.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutics

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value – USD)

    1. 2.1 By Product Type

      1. 2.1.1 Cell and Gene Therapy

      2. 2.1.2 mRNA Therapy

      3. 2.1.3 Viral Vector Vaccines

      4. 2.1.4 Plasmid DNA

      5. 2.1.5 Antisense Oligonucleotides

      6. 2.1.6 siRNA Therapy

    2. 2.2 By Application

      1. 2.2.1 Oncology

      2. 2.2.2 Genetic Disorder

      3. 2.2.3 Infectious Diseases

      4. 2.2.4 Others

    3. 2.3 By End User

      1. 2.3.1 Pharmaceutical and Biotechnology

      2. 2.3.2 Government and Academic Research Institutes

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 United Kingdom

        2. 2.4.2.2 Germany

        3. 2.4.2.3 France

        4. 2.4.2.4 Spain

        5. 2.4.2.5 Italy

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 India

        2. 2.4.3.2 Japan

        3. 2.4.3.3 China

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of the Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Market Size FAQs

The Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Market size is expected to reach USD 4.37 billion in 2024 and grow at a CAGR of 12.60% to reach USD 8.88 billion by 2029.

In 2024, the Nucleic Acid Therapeutics Contract Development And Manufacturing Organization Market size is expected to reach USD 4.37 billion.

Nucleic Acid Therapeutics Contract Development and Manufacturing Organization Market - Growth, and Forecasts (2024 - 2029)